Hirschsprung disease is known to affect colon and cause problems with stool excretion. This disease is hereditary due to absence of a critical nerve cell in the muscle of a newborn baby’s colon. These nerve cells are known to control muscle contractions while food passes through the bowel. Due to absence of such contractions, stool accumulates in the colon. Symptoms of hirschsprung disease include swollen belly, diarrhea, and gastro intestinal issues. A few genetic factor that might possibly increase chances of the disease include having a sibling with the same disease, being born a male. Furthermore, it is associated with certain inherited conditions such as Down’s syndrome and congenital heart diseases. The disease can be treated through administration of prescribed doses of anti-infective, antiemetic, or analgesic drugs.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future ,owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the hirschsprung disease treatment market.
Top Impacting Factors
- The cause of hirschsprung disorder is multifactorial and largely hereditary. It is however liked to cardiovascular diseases and gastrointestinal abnormalities as well as subsequent rise in incidents of these diseases, which act as the major factor driving the growth of hirschsprung treatment market.
- Technological advancements and subsequent increase in investments toward new product approvals and clinical drug trials to find advanced therapeutic ways to get rid of life-threatening diseases is yet another factor driving the market growth for hirschsprung disease treatment.
- Continuous implementation of robust policies by governments to develop new avenues for prevention, detection, and cure of such diseases is anticipated to drive huge market gains around the globe.
- However, frequent incidents of misdiagnosis of other syndromes such as type I sigmoid atresia as hirschsprung disease and the resulting bad word of mouth created is a huge factor visually hampering market growth.
- Additionally, lack of awareness and associated misconception about advanced therapeutic drugs for treatment of hirschsprung and other fatal diseases coupled with lack of efficient healthcare services in third world economies is restricting market penetration.
Key Market Trends
- Advanced stimulations in old technologies and avenues to treat hirschsprung disease coupled with rising disposable income and ability to spend of healthcare among general populace is anticipated to push Europe at the forefront of hirschsprung disease treatment market.
- Unleashed wrath of COVID-19 and its exposure on Indian healthcare system are anticipated to bring in more foreign direct investments and regional players into the Indian healthcare system fray in the coming decade.
- Surgery segment under hirschsprung treatment is anticipated to grow two-fold in revenue and volume, owing to established trust and positive past trends. Among surgeries, pull through surgery and ostomy are the most trending ones.
- Recent studies conducted by University of Helsinki (UHS) concluded that about 1 in every 5000 babies in North America is born without enteric neurons in colon resulting in hirschsprung disease during adulthood. The disease is caused due to mutations in the RET receptor located at the surface of cell resulting in enlargement of colon and constipation in a few cases.
- Children Hospital Los Angeles (CHLA) recently concluded a study promoting the idea of use of stem cells and genetic engineering to treat newborn babies suffering from hirschsprung disease
Key Benefits of the Report
- This study presents the analytical depiction of the hirschsprung disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Hirschsprung Disease Treatment Report
- Which are the leading players active in the hirschsprung disease treatment market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the hirschsprung disease treatment market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is hirschsprung disease treatment?
- What is the hirschsprung disease treatment market prediction in the future?
- What are the current trends and predicted trends?
Hirschsprung Disease Treatment Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By End User |
|
 By Region |
|
 Key Market Players | Bayer Healthcare, Cipla Ltd., Abbott, Sanofi, Pfizer, Novartis AG, Bristol-Myers Squibb, Merck and Co., Johnson and Johnson, Astellas Pharma |
Loading Table Of Content...
